Study Details

Back to Search Results

A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients with Rheumatoid Arthritis taking Methotrexate

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02884635

Astellas Study ID

The unique identification code given by the study sponsor.

1707-CL-3001

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Rheumatoid Arthritis

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

N/A - N/A

Sex

Female

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Sep 2016 - Oct 2017

Masking

Double (Participant, Investigator)

Enrollment number

72

Phase IIa Study of ASP1707 A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Phase 2a Study of ASP1707 in Postmenopausal Female Patients with Rheumatoid Arthritis (RA) taking Methotrexate (MTX)

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients with Rheumatoid Arthritis taking Methotrexate? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP00014

Kumamoto, Japan

Site JP00021

Kanagawa, Japan

Site JP00027

Tokyo, Japan

Site JP00002

Hokkaido, Japan

Site JP00015

Kumamoto, Japan

Site JP00025

Fukui, Japan

Site JP00004

Iwate, Japan

Site JP00024

Gunma, Japan

Site JP00022

Aichi, Japan

Site JP00001

Hokkaido, Japan

Site JP00020

Oita, Japan

Site JP00010

Hiroshima, Japan

Site JP00008

Shizuoka, Japan

Site JP00017

Chiba, Japan

Site JP00003

Hokkaido, Japan

Site JP00009

Shizuoka, Japan

Site JP00007

Kanagawa, Japan

Site JP00006

Gunma, Japan

Site JP00016

Kagoshima, Japan

Site JP00018

Fukuoka, Japan

Site JP00013

Nagasaki, Japan

Site JP00012

Fukuoka, Japan

Site JP00023

Aichi, Japan

Site JP00011

Hiroshima, Japan

Site JP00019

Fukuoka, Japan

Site JP00026

Ehime, Japan

Site JP00005

Iwate, Japan

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo